公开(公告)号：US11938247B2

公开(公告)日：2024-03-26

申请号：US16609887

申请日：2018-05-02

Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Sung Won Kim ,  Jung Yeon Lim ,  Sun Hwa Park ,  Byeong Gon Yoon ,  Dong-Woo Cho ,  Jinah Jang ,  Seok Won Kim

IPC: A61L27/38 ,  A61L27/20 ,  A61L27/24 ,  A61L27/52 ,  A61L27/54

CPC classification number: A61L27/3834 ,  A61L27/20 ,  A61L27/24 ,  A61L27/52 ,  A61L27/54 ,  A61L2400/06

Abstract: Provided are a method for fabricating a human nasal turbinate-derived mesenchymal stem cell-based 3D bioprinted construct, and a use thereof, wherein the human nasal turbinate-derived mesenchymal stem cell-based, 3D bioprinted construct is advantageous over conventional mesenchymal stem cell-based, 3D bioprinted constructs in that the former can survive and proliferate stably in vitro and/or in vivo and shows high osteogenic differentiation ability as well, therefore is expected to make a great contribution to the practical use of cellular therapeutic agents.

公开(公告)号：US11612620B2

公开(公告)日：2023-03-28

申请号：US16633618

申请日：2018-06-21

Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Sung Won Kim ,  Seung Ki Kwok ,  Jaeseon Lee ,  Sun hwa Park ,  Jung Yeon Lim

IPC: A61K35/28 ,  A61P19/02

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating rheumatoid arthritis, and a stem cell therapeutic agent for treating rheumatoid arthritis, comprising nasal inferior turbinate-derived mesenchymal stem cells as an active ingredient. Nasal inferior turbinate-derived mesenchymal stem cells of the present invention have the effects of reducing the production of interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), immunoglobulin G2 (IgG2a) which is an inflammation-inducing factor, and/or the proliferative ability of lymph node T cells, increasing interleukin-10 (IL-10) and/or regulatory T-cells (Treg, CD4+CD25+foxp3+ cell) that contribute to immune tolerance in spleen cells, and inhibiting the proliferation of human T-cells. The nasal inferior turbinate-derived mesenchymal stem cells have a safer acquisition process than existing mesenchymal stem cells and can be acquired in sufficient amounts within a desired period of time, thus allowing mesenchymal stem cells to be acquired at low cost and high efficiency. Moreover, since the nasal inferior turbinate-derived mesenchymal stem cells have the same genetic origin as individuals administered therewith there are few side effects, the nasal inferior turbinate-derived mesenchymal stem cells can be usefully used for preventing or treating in individually tailored immunocompatible rheumatoid arthritis.